Comprehensive Stock Comparison
Compare Kymera Therapeutics, Inc. (KYMR) vs Akari Therapeutics, Plc (AKTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | AKTX | Beta 0.63 vs KYMR's 1.31 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | KYMR | +191.4% vs AKTX's -72.9% |
| Efficiency (ROA) | KYMR | -17.9% ROA vs AKTX's -34.7%, ROIC -24.9% vs -172.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Kymera Therapeutics is a biopharmaceutical company developing targeted protein degraders — small molecules that harness the body's natural protein degradation system to eliminate disease-causing proteins. It generates revenue primarily through strategic partnerships and milestone payments from pharmaceutical collaborators — with potential future revenue from drug sales if clinical candidates succeed. The company's key advantage is its proprietary Pegasus platform for discovering novel protein degraders, which targets previously "undruggable" proteins and creates a pipeline of first-in-class therapies.
Akari Therapeutics is a clinical-stage biopharmaceutical company developing advanced therapies for autoimmune and inflammatory diseases. It generates no revenue currently — its business model depends on advancing its lead candidate nomacopan through clinical trials to eventually secure regulatory approvals and commercialization partnerships. The company's key advantage lies in nomacopan's dual mechanism of action targeting both complement and leukotriene pathways — a differentiated approach that could offer superior efficacy in treating complex inflammatory conditions.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
KYMR leads in 3 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 2 categories are tied.
Financial Metrics (TTM)
KYMR and AKTX operate at a comparable scale, with $39M and $0 in trailing revenue.
| Metric | KYMRKymera Therapeuti… | AKTXAkari Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $39M | $0 |
| EBITDAEarnings before interest/tax | -$349M | -$17M |
| Net IncomeAfter-tax profit | -$311M | -$16M |
| Free Cash FlowCash after capex | -$234M | -$10M |
| Gross MarginGross profit ÷ Revenue | +100.0% | — |
| Operating MarginEBIT ÷ Revenue | -8.9% | — |
| Net MarginNet income ÷ Revenue | -7.9% | — |
| FCF MarginFCF ÷ Revenue | -6.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -61.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -11.4% | -80.2% |
Valuation Metrics
| Metric | KYMRKymera Therapeuti… | AKTXAkari Therapeutic… |
|---|---|---|
| Market CapShares × price | $7.4B | $12.6B |
| Enterprise ValueMkt cap + debt − cash | $7.2B | $12.6B |
| Trailing P/EPrice ÷ TTM EPS | -24.76x | -0.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 189.51x | — |
| Price / BookPrice ÷ Book value/share | 4.88x | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
KYMR delivers a -19.7% return on equity — every $100 of shareholder capital generates $-20 in annual profit, vs $-69 for AKTX. KYMR carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to AKTX's 0.15x. On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs AKTX's 3/9, reflecting mixed financial health.
| Metric | KYMRKymera Therapeuti… | AKTXAkari Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -19.7% | -69.4% |
| ROA (TTM)Return on assets | -17.9% | -34.7% |
| ROICReturn on invested capital | -24.9% | -172.5% |
| ROCEReturn on capital employed | -27.2% | -142.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.05x | 0.15x |
| Net DebtTotal debt minus cash | -$275M | $661,000 |
| Cash & Equiv.Liquid assets | $357M | $3M |
| Total DebtShort + long-term debt | $82M | $3M |
| Interest CoverageEBIT ÷ Interest expense | -1403.21x | -47.14x |
Total Returns (with DRIP)
A $10,000 investment in KYMR five years ago would be worth $18,851 today (with dividends reinvested), compared to $35 for AKTX. Over the past 12 months, KYMR leads with a +191.4% total return vs AKTX's -72.9%. The 3-year compound annual growth rate (CAGR) favors KYMR at 42.8% vs AKTX's -67.5% — a key indicator of consistent wealth creation.
| Metric | KYMRKymera Therapeuti… | AKTXAkari Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | +25.5% | -18.6% |
| 1-Year ReturnPast 12 months | +191.4% | -72.9% |
| 3-Year ReturnCumulative with dividends | +191.1% | -96.6% |
| 5-Year ReturnCumulative with dividends | +88.5% | -99.6% |
| 10-Year ReturnCumulative with dividends | +174.7% | -99.9% |
| CAGR (3Y)Annualised 3-year return | +42.8% | -67.5% |
Risk & Volatility
AKTX is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than KYMR's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 88.7% from its 52-week high vs AKTX's 13.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KYMRKymera Therapeuti… | AKTXAkari Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.63x |
| 52-Week HighHighest price in past year | $103.00 | $1.73 |
| 52-Week LowLowest price in past year | $19.45 | $0.22 |
| % of 52W HighCurrent price vs 52-week peak | +88.7% | +13.7% |
| RSI (14)Momentum oscillator 0–100 | 77.9 | 52.2 |
| Avg Volume (50D)Average daily shares traded | 620K | 387K |
Analyst Outlook
Wall Street rates KYMR as "Buy" and AKTX as "Buy". Consensus price targets imply 12601.1% upside for AKTX (target: $30) vs 28.4% for KYMR (target: $117).
| Metric | KYMRKymera Therapeuti… | AKTXAkari Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $117.31 | $30.00 |
| # AnalystsCovering analysts | 26 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Kymera Therapeutics… (KYMR) | 100 | 227.36 | +127.4% |
| Akari Therapeutics,… (AKTX) | 100 | 0.72 | -99.3% |
Kymera Therapeutics… (KYMR) returned +89% over 5 years vs Akari Therapeutics,… (AKTX)'s -100%. A $10,000 investment in KYMR 5 years ago would be worth $18,851 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kymera Therapeutics… (KYMR) | $0.00 | $39M | — |
| Akari Therapeutics,… (AKTX) | $0.00 | $0.00 | — |
Chart 3EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kymera Therapeutics… (KYMR) | -0.48 | -3.69 | -668.8% |
| Akari Therapeutics,… (AKTX) | -3,080 | -1,660 | +46.1% |
Chart 4Free Cash Flow — 5 Years
Kymera Therapeutics, Inc. generated $-234M FCF in 2025 (-80% vs 2021). Akari Therapeutics, Plc generated $-13M FCF in 2024 (+33% vs 2021).
KYMR vs AKTX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is KYMR or AKTX a better buy right now?
Analysts rate Kymera Therapeutics, Inc. (KYMR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KYMR or AKTX?
Over the past 5 years, Kymera Therapeutics, Inc. (KYMR) delivered a total return of +88.5%, compared to -99.6% for Akari Therapeutics, Plc (AKTX). A $10,000 investment in KYMR five years ago would be worth approximately $19K today (assuming dividends reinvested). Over 10 years, the gap is even starker: KYMR returned +174.7% versus AKTX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KYMR or AKTX?
By beta (market sensitivity over 5 years), Akari Therapeutics, Plc (AKTX) is the lower-risk stock at 0.63β versus Kymera Therapeutics, Inc.'s 1.31β — meaning KYMR is approximately 108% more volatile than AKTX relative to the S&P 500. On balance sheet safety, Kymera Therapeutics, Inc. (KYMR) carries a lower debt/equity ratio of 5% versus 15% for Akari Therapeutics, Plc — giving it more financial flexibility in a downturn.
04Which has better profit margins — KYMR or AKTX?
Akari Therapeutics, Plc (AKTX) is the more profitable company, earning 0.0% net margin versus -794.4% for Kymera Therapeutics, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKTX leads at 0.0% versus -891.3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KYMR or AKTX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KYMR or AKTX better for a retirement portfolio?
For long-horizon retirement investors, Akari Therapeutics, Plc (AKTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.63)). Both have compounded well over 10 years (AKTX: -99.9%, KYMR: +174.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KYMR and AKTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.